|
Research Interests:
Dr. DeLeo's major research interest is the molecular characterization of highly restricted tumor rejection antigens of chemically induced sarcomas of inbred mice. Current research focuses on a Mr 110,000 glycoprotein, gp110, which has been isolated from antigenically distinct sarcomas and shown to have tumor rejection-inducing activityrestricted to the tumor of its origin. Furthermore, Gp110 isolated from the Meth A sarcoma has been shown to express an epitope recognized by a cloned, CD8+ anti-Meth A CTL. The cDNA encoding gp110 is currently being cloned, and the potential of gp110 being a human tumor antigen is being studied.
Selected Publications:
View Dr. DeLeo's publications on PubMed
Albers AE, Ferris RL, Kim GG, Chikamatsu K, Deleo AB, Whiteside TL. Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother. 2005 Jun 16; [Epub ahead of print]
Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tuting T, Kaczmarek E, DeLeo AB. Impact of p53-based immunization on primary chemically-induced tumors. Int J Cancer. 2005 Mar 1;113(6):961-70.
Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res. 2003 Jul 1;63(13):3675-81.
|
